Pharvaris/$PHVS

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Pharvaris

Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.

Ticker

$PHVS
Sector
Primary listing

Employees

-

Headquarters

Zug, Switzerland

Pharvaris Metrics

BasicAdvanced
$1.6B
-
-$3.59
-2.81
-

What the Analysts think about Pharvaris

Analyst ratings (Buy, Hold, Sell) for Pharvaris stock.

Bulls say / Bears say

Deucrictibant received orphan designation from the European Commission on March 25, 2025, granting 10 years of market exclusivity in the EU and strengthening its commercial outlook (EMA).
The RAPIDe-3 pivotal Phase 3 on-demand study reached target enrollment of approximately 120 participants in March 2025, reinforcing confidence in the program’s execution and timeline (Nasdaq).
The FDA granted TQT study waivers for both extended- and immediate-release formulations of deucrictibant in May 2025, streamlining the development pathway by eliminating dedicated cardiac safety trials (Nasdaq).
2024 net loss reached €134 million, up from €100.9 million in 2023, reflecting mounting operating deficits amid late‐stage development (Nasdaq).
Full‐year 2024 R&D expenses surged to €98.6 million, a 50 percent increase year‐over‐year, underscoring escalating development costs without current revenue support (Nasdaq).
Cash and cash equivalents fell by €110 million year-over-year to €281 million as of December 31, 2024, indicating a high burn rate that may necessitate additional financing before commercialization (Nasdaq).
Data summarised monthly by Lightyear AI. Last updated on 3 Oct 2025.

Pharvaris Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Pharvaris Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PHVS

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs